» Articles » PMID: 28369781

A Big Data Approach to the Development of Mixed-effects Models for Seizure Count Data

Overview
Journal Epilepsia
Specialty Neurology
Date 2017 Apr 4
PMID 28369781
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Our objective was to develop a generalized linear mixed model for predicting seizure count that is useful in the design and analysis of clinical trials. This model also may benefit the design and interpretation of seizure-recording paradigms. Most existing seizure count models do not include children, and there is currently no consensus regarding the most suitable model that can be applied to children and adults. Therefore, an additional objective was to develop a model that accounts for both adult and pediatric epilepsy.

Methods: Using data from SeizureTracker.com, a patient-reported seizure diary tool with >1.2 million recorded seizures across 8 years, we evaluated the appropriateness of Poisson, negative binomial, zero-inflated negative binomial, and modified negative binomial models for seizure count data based on minimization of the Bayesian information criterion. Generalized linear mixed-effects models were used to account for demographic and etiologic covariates and for autocorrelation structure. Holdout cross-validation was used to evaluate predictive accuracy in simulating seizure frequencies.

Results: For both adults and children, we found that a negative binomial model with autocorrelation over 1 day was optimal. Using holdout cross-validation, the proposed model was found to provide accurate simulation of seizure counts for patients with up to four seizures per day.

Significance: The optimal model can be used to generate more realistic simulated patient data with very few input parameters. The availability of a parsimonious, realistic virtual patient model can be of great utility in simulations of phase II/III clinical trials, epilepsy monitoring units, outpatient biosensors, and mobile Health (mHealth) applications.

Citing Articles

Artificial Intelligence in Pediatric Epilepsy Detection: Balancing Effectiveness With Ethical Considerations for Welfare.

Mourid M, Irfan H, Oduoye M Health Sci Rep. 2025; 8(1):e70372.

PMID: 39846037 PMC: 11751886. DOI: 10.1002/hsr2.70372.


BAYESIAN NON-HOMOGENEOUS HIDDEN MARKOV MODEL WITH VARIABLE SELECTION FOR INVESTIGATING DRIVERS OF SEIZURE RISK CYCLING.

Wang E, Chiang S, Haneef Z, Rao V, Moss R, Vannucci M Ann Appl Stat. 2024; 17(1):333-356.

PMID: 38486612 PMC: 10939012. DOI: 10.1214/22-aoas1630.


State Space Modeling of Event Count Time Series.

Moontaha S, Arnrich B, Galka A Entropy (Basel). 2023; 25(10).

PMID: 37895494 PMC: 10606130. DOI: 10.3390/e25101372.


Flexible realistic simulation of seizure occurrence recapitulating statistical properties of seizure diaries.

Goldenholz D, Westover M Epilepsia. 2022; 64(2):396-405.

PMID: 36401798 PMC: 9905290. DOI: 10.1111/epi.17471.


Seizure count forecasting to aid diagnostic testing in epilepsy.

Wang E, Chiang S, Cleboski S, Rao V, Vannucci M, Haneef Z Epilepsia. 2022; 63(12):3156-3167.

PMID: 36149301 PMC: 11025604. DOI: 10.1111/epi.17415.


References
1.
Skidmore C . Adult Focal Epilepsies. Continuum (Minneap Minn). 2016; 22(1 Epilepsy):94-115. DOI: 10.1212/CON.0000000000000290. View

2.
Troconiz I, Plan E, Miller R, Karlsson M . Modelling overdispersion and Markovian features in count data. J Pharmacokinet Pharmacodyn. 2009; 36(5):461-77. DOI: 10.1007/s10928-009-9131-y. View

3.
Elger C, Brodie M, Anhut H, Lee C, Barrett J . Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia. 2006; 46(12):1926-36. DOI: 10.1111/j.1528-1167.2005.00341.x. View

4.
Balish M, Albert P, Theodore W . Seizure frequency in intractable partial epilepsy: a statistical analysis. Epilepsia. 1991; 32(5):642-9. DOI: 10.1111/j.1528-1157.1991.tb04703.x. View

5.
Cook R, Wei W . Conditional analysis of mixed Poisson processes with baseline counts: implications for trial design and analysis. Biostatistics. 2003; 4(3):479-94. DOI: 10.1093/biostatistics/4.3.479. View